Status:
COMPLETED
The Effects of Oxycodone Versus Sufentanil on Pain and Inflammatory Response After TACE
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Conditions:
Hepatocellular Carcinoma
Transcatheter Arterial Chemoembolization
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this randomized, double-blind trial was to compare the effects of preemptive Oxycodone and sufentanil at the same dose on pain and inflammatory response after transcatheter arterial che...
Detailed Description
Transcatheter arterial chemoembolization (TACE) is currently considered as the treatment for unresectable hepatocellular carcinoma (HCC). Due to sudden blockage of the main blood vessels supplying the...
Eligibility Criteria
Inclusion
- Age ≥18 years;
- Presence of histologically confirmed or clinically diagnosed hepatocellular carcinoma (fulfilling the criteria for lesions with typical imaging);
- Presence of Child-Pugh class A or B disease;
- Absence of benefit from a treatment of established efficacy such as resection and local ablation;
- ECOG:0-2.
Exclusion
- Extrahepatic metastasis and/or microvascular invasion;
- Severe liver and kidney dysfunction;
- Uncontrolled or significant cardiovascular disease; Autoimmune hepatitis; Long term use of opioids, steroid hormones, and non steroidal anti-inflammatory drugs; Abnormal elevation of C-reactive protein (CRP); Increased white blood cells (\>11000/mm3); Study Drugs allergy; Patients who were treated within 4 weeks after COVID-19 infection was diagnosed.
Key Trial Info
Start Date :
August 7 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 25 2023
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT06041425
Start Date
August 7 2023
End Date
December 25 2023
Last Update
February 28 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital with Nanjing Medical University
Nanjing, Jiangsu, China, 210029